Risk factors for multidrug resistant bacterial infection in infants with bronchopulmonary dysplasia re-hospitalized due to lower respiratory tract infection: a case-control study

To evaluate the epidemiological characteristics and risk factors for multidrug-resistant bacterial infection (MDRI) in infants with bronchopulmonary dysplasia (BPD) readmitted to the hospital due to lower respiratory tract infection (LRTI), providing a basis for the clinical prevention and treatment of MDRI.A retrospective analysis of readmission due to LRTI in infants with BPD within 1 year corrected age from October 2012 to December 2020 was performed. Twenty-nine children with MDRI were selected as the case group, and 80 children without MDRI during the same period served as the control group. We reviewed and collected relevant infants’ neonatal hospitalization experience, broad-spectrum antibiotic (BSA) selection, and microbiological data. BSA included carbapenem antibiotics, third-generation cephalosporins and cephalosporin/β-lactamase inhibitor combinations, and penicillin/β-lactamase inhibitor (P/BLI) combinations.The length of stay in hospitalized patients with MDRI was significantly prolonged (p < 0.05), and the BSA use rate was high (>94.1%). Single-level factor analyses showed that nosocomial infection and the P/BLI usage rate in the Neonatal Intensive Care Unit (NICU) were related to MDRIs (all p < 0.05). NICU-MDRI, BSA, dual antibiotics, and mechanical ventilation were not significantly associated with MDRIs on readmission (all p > 0.05). Binary logistic regression analysis indicated nosocomial infection as an independent risk factor related to MDRIs (Odds ratio (OR) 5.3, 95% confidence interval (CI) 1.7–16.4).Nosocomial infection remains the most important risk factor for MDRI in BPD infants. For infants with BPD, more cautions should be taken on whether to choose BSA directly based on the bacterial species infected during the NICU or the long-term hospitalization history.

Broad-spectrum antibiotics; Nosocomial infection; Multidrug resistant bacteria infections; Bronchopulmonary dysplasia

[1] WHO. Critically important antimicrobials for human medicine. 6th edn. World Health Organization: Geneva. 2019.

[2] Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. American Journal of Infection Control. 2008; 36: 309–332.

[3] Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. Atlanta; 2019.

[4] Alonso-Ojembarrena A, Martínez-Díaz JV, Lechuga-Sancho AM, Galán-Sánchez F, Lubián-López SP. Broad spectrum antibiotics in newborns increase multi-drug resistant infections. Journal of Chemotherapy. 2019; 31: 81–85.

[5] Köck R, Becker K, Idelevich EA, Jurke A, Glasner C, Hendrix R, et al. Prevention and control of multidrug-resistant bacteria in the Netherlands and Germany—the impact of healthcare structures. International Journal of Environmental Research and Public Health. 2020; 17: 2337.

[6] Morris S, Cerceo E. Trends, epidemiology, and management of multi-drug resistant gram-negative bacterial infections in the hospitalized setting. Antibiotics. 2020; 9: 196.

[7] Keller RL, Feng R, Demauro SB, Ferkol T, Hardie W, Rogers EE, et al. Bronchopulmonary dysplasia and perinatal characteristics predict 1-year respiratory outcomes in newborns born at extremely low gestational age: a prospective cohort study. The Journal of pediatrics. 2017; 187: 89–97.

[8] Jensen EA, Dysart K, Gantz MG, McDonald S, Bamat NA, Keszler M, et al. The diagnosis of bronchopulmonary dysplasia in very preterm infants. An evidence-based approach. American Journal of Respiratory and Critical Care Medicine. 2019; 200: 751–759.

[9] Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection. 2012; 18: 268–281.

[10] WHO. WHO child growth standards and the identification of severe acute malnutrition in infants and children: a joint statement by the world health organization and the united nations children’s fund. 3.0M. World Health Organization: Geneva. 2009.

[11] Emmanuel MA, Widmer A, Frei R, Pargger H, Tuchscherer D, Marsch S, et al. ESBL-colonization at ICU admission: impact on subsequent infection, carbapenem-consumption, and outcome. Infection Control & Hospital Epidemiology. 2019; 40: 408–413.

[12] El Mekes A, Zahlane K, Ait Said L, Tadlaoui Ouafi A, Barakate M. The clinical and epidemiological risk factors of infections due to multi-drug resistant bacteria in an adult intensive care unit of university hospital center in Marrakesh-Morocco. Journal of Infection and Public Health. 2020; 13: 637–643.

[13] Wang Z, Xia Z. What we can do? The risk factors for multi-drug resistant infection in pediatric intensive care unit (PICU): a case-control study. Italian Journal of Pediatrics. 2020; 46: 17.

[14] Ibrahim MK, Zambruni M, Melby CL, Melby PC. Impact of childhood malnutrition on host defense and infection. Clinical Microbiology Reviews. 2017; 30: 919–971.

[15] Fernando SA, Gray TJ, Gottlieb T. Healthcare-acquired infections: prevention strategies. Internal Medicine Journal. 2017; 47: 1341–1351.

[16] Cerceo E, Deitelzweig SB, Sherman BM, Amin AN. Multidrug-resistant gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options. Microbial Drug Resistance. 2016; 22: 412–431.

[17] van Duin D, Paterson DL. Multidrug-resistant bacteria in the community: an update. Infectious Disease Clinics of North America. 2020; 34: 709–722.

[18] Mirzaii M, Jamshidi S, Zamanzadeh M, Marashifard M, Malek Hosseini SAA, Haeili M, et al. Determination of gyrA and parC mutations and prevalence of plasmid-mediated quinolone resistance genes in Escherichia coli and Klebsiella pneumoniae isolated from patients with urinary tract infection in Iran. Journal of Global Antimicrobial Resistance. 2018; 13: 197–200.